-
-
-
-
-
-
-
Abbvie (ABBV) PT Raised to $261 at Guggenheim
-
-
-
-
-
-
-
AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio
-
-
-
-
-
-
-
AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results
-
-
-
-
-
-
-
Analysts expect AbbVie’s core franchises to offset R&D costs ahead of Q3 earnings
-
-
-
-
-
-
-
AbbVie to Acquire Gilgamesh Pharmaceuticals' Bretisilocin, a Novel, Investigational Therapy for Major Depressive Disorder, Expanding Psychiatry Pipeline
-
-
-
-
-
-
-
Morgan Stanley on Abbvie (ABBV) Buying Capstan: 'We view this acquisition as an incremental positive'
-
-
-
-
-
-
-
AbbVie's Allergan Aesthetics set to launch three new training centers in U.S.
-
1,181,574 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

